Prescription drug · ANDA
Imipramine Pamoate NDC 70518-4730
Imipramine pamoate 75 mg/1 · Capsule · Oral · REMEDYREPACK INC.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70518-4730-0 | 70518473000 | 50 POUCH in 1 BOX (70518-4730-0) / 1 CAPSULE in 1 POUCH (70518-4730-1)Marketed from Aug 20, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Imipramine Pamoate
- Generic name (nonproprietary)
- imipramine pamoate
- Active ingredients
- Imipramine pamoate — 75 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- REMEDYREPACK INC.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 090444
- Marketing start
- Listing expires
- Identifiers
- Product ID 70518-4730_59799493-0088-734e-e063-6394a90a67edSPL ID 59799493-0088-734e-e063-6394a90a67edSPL set ID 76f412fd-f476-40c6-8aa7-9abced75c3e8RxCUI 835572UNII MC34P30298
- Pharmacologic class
- Tricyclic Antidepressant
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470518473000followed by a unit qualifier and the quantityPackage 70518-4730-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 090444
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Imipramine Pamoate | Imipramine pamoate 125 mg/1 | CapsuleOral | Lupin Pharmaceuticals, Inc. | 68180-316 |
| Imipramine Pamoate | Imipramine pamoate 75 mg/1 | CapsuleOral | Lupin Pharmaceuticals, Inc. | 68180-314 |
| Imipramine Pamoate | Imipramine pamoate 100 mg/1 | CapsuleOral | Lupin Pharmaceuticals, Inc. | 68180-315 |
| Imipramine Pamoate | Imipramine pamoate 150 mg/1 | CapsuleOral | Lupin Pharmaceuticals, Inc. | 68180-317 |